Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Siena, Italy.
Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Siena, Italy.
J Clin Densitom. 2010 Jan-Mar;13(1):77-83. doi: 10.1016/j.jocd.2009.10.002.
Reduced areal bone mineral density (aBMD) is a common feature of neurofibromatosis type 1 (NF1). Moreover, in recent years there has been a growing interest in using quantitative ultrasound (QUS) for the evaluation of bone status. In 55 NF1 subjects (mean age: 9.3+/-5.4yr) and in 51 age- and sex-matched controls we measured aBMD at lumbar spine, at femoral neck (aBMD-FN), and at total femur (aBMD-T). Apparent volumetric bone mineral density (BMAD) was also calculated. In all subjects, QUS parameters at phalanges were evaluated. In NF1 subjects, the values of aBMD and BMAD were lower than in controls at all skeletal sites, but the difference reached statistical significance only at femoral sites (p<0.05). Both aBMD and QUS parameters were lower in those NF1 subjects with skeletal abnormalities than in those without abnormalities, but the difference was statistically significant (p<0.05) only for aBMD-FN and aBMD-T. Multiple regression analysis showed that the subjects with skeletal abnormalities had a higher risk of having bone transmission time (BTT) Z-score and aBMD Z-score at femoral sites less than -1. In conclusion, our results suggest that aBMD and QUS represent useful tools in evaluating the impairment of bone status in NF1 subjects.
骨密度降低是 1 型神经纤维瘤病(NF1)的常见特征。此外,近年来人们越来越关注使用定量超声(QUS)来评估骨状况。在 55 名 NF1 患者(平均年龄:9.3±5.4 岁)和 51 名年龄和性别匹配的对照组中,我们测量了腰椎、股骨颈(aBMD-FN)和全股骨(aBMD-T)的 aBMD。还计算了表观体积骨密度(BMAD)。在所有受试者中,评估了指骨的 QUS 参数。在 NF1 患者中,所有骨骼部位的 aBMD 和 BMAD 值均低于对照组,但仅在股骨部位差异具有统计学意义(p<0.05)。在有骨骼异常的 NF1 患者中,aBMD 和 QUS 参数均低于无骨骼异常的患者,但仅在 aBMD-FN 和 aBMD-T 方面差异具有统计学意义(p<0.05)。多元回归分析显示,有骨骼异常的患者骨传播时间(BTT)Z 评分和股骨部位的 aBMD Z 评分低于-1 的风险更高。总之,我们的结果表明,aBMD 和 QUS 是评估 NF1 患者骨状况受损的有用工具。